CRON - Cronos Group Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
15.07
+0.17 (+1.14%)
At close: 4:00PM EST

15.20 +0.13 (0.86%)
Pre-Market: 7:18AM EST

Stock chart is not supported by your current browser
Previous Close14.90
Open15.20
Bid15.18 x 1000
Ask15.20 x 3000
Day's Range14.81 - 16.05
52 Week Range5.12 - 16.07
Volume11,270
Avg. Volume9,710,356
Market Cap2.687B
Beta (3Y Monthly)3.41
PE Ratio (TTM)N/A
EPS (TTM)-0.03
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • ACCESSWIRE18 hours ago

    4 Marijuana Stocks Getting A Boost From Today's Headlines

    With the global medical marijuana market predicted to reach $55.0 billion by 2024, according to a new research study published by Global Market Insights, Inc, it stands to reason that companies with the ability to combine the complex medical applications of cannabis with integrative healthcare frameworks could create potential opportunities from entering the nascent marijuana industry. ), and GW Pharmaceuticals plc (GWPH) are four pot stocks representing companies helping the whole of their industry move forward. Premier Health Group (PHGRF) (PHGI) is a company focused on redesigning how medical care is received and implementing nuanced practical applications for cannabis products in the healthcare space.

  • ACCESSWIRE21 hours ago

    4 Marijuana Stocks Making Moves On News This Month

    CORAL GABLES, FL/ ACCESSWIRE / January 22, 2019 / The marijuana stock market has seen some of the best days in its history over the course of the past two weeks or so. Since the passing of the US Farm Bill, companies in the cannabis industry have been working to build out their hemp operations and manufacturing. With the new year already one month older, Premier Health Group (PHGRF) (PHGI), Cronos Group Inc (CRON), Aphria Inc (APHA) (APHA), and Canopy Growth Corporation (CGC) are four pot stocks worth looking into on Tuesday.

  • InvestorPlace22 hours ago

    It’s Time to Hit Pause on Aphria Stock Until It Clears This Issue

    Thanks to a combination of youth and controversy, marijuana companies experienced both phenomenal growth and devastating lows last year. But despite this acknowledged volatility, cannabis firm Aphria (NYSE:APHA) managed to shock even hardened investors. Over the trailing three months, Aphria stock hemorrhaged 55%. Such a dramatic fallout never occurs without a reason. For APHA stock, the underlying company found itself in a short-seller's crosshairs. Last month, Hindenburg Research made a painful accusation, calling Aphria a "shell game with a cannabis business on the side." At the heart of the controversy is the company's Latin American acquisitions, which Hindenburg labeled "largely worthless." Specifically, the short-seller alleges that APHA insiders had a financial stake in the acquired assets. Therefore, the buyouts had little to do with the raising value for Aphria stock. Instead, management enriched themselves at the shareholders' expense. InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's not a stretch to say that the marijuana industry doesn't enjoy the most philanthropic of reputations. When the accusations first broke, APHA stock wasn't the only victim. Like a tidal wave, the controversy took down major players like Tilray (NASDAQ:TLRY) and Canopy Growth (NYSE:CGC). * The 10 Best Index Funds to Buy and Hold Unfortunately for passersby, guilt by association is a risk of doing business in the botanical industry. But with several competitors, including Aphria stock, experiencing significant bullishness, did the bears prematurely condemn APHA? ### Aphria Stock Remains Ambiguous On one hand, we can appreciate why many investors view Hindenburg's accusations with cynicism. As the short-seller, they have a vested interest in moving APHA stock in a particular direction. They're not disseminating their accusations for the public's benefit. Furthermore, this is not the first time we've seen bearish intrusions in this sector, nor will it be the last. As I mentioned last month, notorious short-seller Citron Research blasted Cronos Group (NASDAQ:CRON) for deceptive business practices. Today, Cronos has a partnership with tobacco giant Altria Group (NYSE:MO). It's also one of the best-performing marijuana stocks. Bears love picking on cannabis firms due to the relative lack of knowledge. This is still a fresh investment sector prone to extreme emotions. In addition, low trading volume means that shorting specialists can use their influence to their advantage. On the other hand, prospective buyers interested in Aphria stock are still waiting for an official response. After Hindenburg leveled its accusations, APHA's management team declared them as libelous. They promised a counterattack that would clear their name. Naturally, the question is, where is it? We're now almost two months into the allegation's reveal, and we haven't heard a peep. Due to the gravity of the situation, management should have substantively defended themselves right away. Failing that, the next best time was during the second-quarter conference call. As our own Vince Martin asserted, every cannabis firm is also their industry's public-relations officer. He wrote: "This is a new sector, and a number of pot companies have inexperienced managers and are or were listed on the pink sheets. So the space still needs more credibility. Aphria can add to the sector's credibility or undermine it." At the very least, Aphria stock is a distraction. ### I Like the Idea of Aphria, But Not APHA Stock If you're considering APHA stock, you ultimately face two choices: either you believe the accusations regarding insider dealings, or you don't. The other negatives, such as disappointing financial performances, don't really matter right now. For cannabis firms to achieve lasting success, they must lay down the foundations today. This brings up an awfully difficult dilemma. If the company did everything the right way, I'd look at Aphria stock as a long-term buy. Thanks to its low production costs and its robust output capacity, you get a lot for your money. But the value of this discount hinges on Hindenburg's ominous dark cloud. Based on my research, the consensus toward Aphria stock appears split. Many harbor skepticism, especially because this sector is so controversial. But we also have voices like The Motley Fool's Keith Speights. He believes that Aphria's special committee assigned to investigate the allegations will not reveal anything overly damaging. * The 3 Best Telecom Stocks to Buy to Fortify Your Portfolio This Year I'm not so sure. For one thing, we've seen questionable behavior from APHA before. Back in the early spring of 2018, executives failed to properly disclose its equity stake in takeover target Nuuvera. This was the first indicator that the higher-ups care more about enriching themselves rather than their shareholders. Still, people usually forgive a one-off incident as a mistake. But when an almost-identical controversy repeats itself, it's not a mistake … it's a pattern. The bottom line is that I like the idea of Aphria: an undervalued, low-cost cannabis producer. But until it clears its name, APHA stock is a huge gamble. As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 High-Growth Stocks for the Return of the Bull * The 10 Best Index Funds to Buy and Hold * 10 Lithium Stocks to Buy Despite the Market's Irrationality Compare Brokers The post It's Time to Hit Pause on Aphria Stock Until It Clears This Issue appeared first on InvestorPlace.

  • High Times Expands Conference Portfolio in Europe with $7 Million Acquisition of Spannabis
    IPO-Edge.com2 days ago

    High Times Expands Conference Portfolio in Europe with $7 Million Acquisition of Spannabis

    High Times Purchases Spain’s Spannabis for $7 Million in Cash and Stock, Plus Milestone Payments   By John Jannarone The parent of High Times magazine has purchased Spain’s Spannabis for $7 million in cash and stock, adding Europe’s largest marijuana industry event to its growing conference portfolio. Spannabis’s parent company, Feria Del Canamo, S.L., will […]

  • High Times Expands Conference Portfolio in Europe with $7 Million Acquisition of Spannabis
    IPO Edge2 days ago

    High Times Expands Conference Portfolio in Europe with $7 Million Acquisition of Spannabis

    High Times Purchases Spain’s Spannabis for $7 Million in Cash and Stock, Plus Milestone Payments   By John Jannarone The parent of High Times magazine has purchased Spain’s Spannabis for $7 million in cash and stock, adding Europe’s largest marijuana industry event to its growing conference portfolio. Spannabis’s parent company, Feria Del Canamo, S.L., will […]

  • ACCESSWIRE2 days ago

    Cannabis Bargains to Boost Your Profits

    HENDERSON, NV / ACCESSWIRE / January 21, 2019 / Last year, Canada legalized cannabis, Michigan legalized cannabis for recreational use, Missouri and Utah legalized it for medical applications, and U.S. ...

  • Cronos Group (CRON) Catches Eye: Stock Jumps 9.1%
    Zacks2 days ago

    Cronos Group (CRON) Catches Eye: Stock Jumps 9.1%

    Cronos Group (CRON) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

  • Cronos Group Inc. Announces Mailing of Meeting Materials in Connection with Upcoming Special Meeting of Shareholders
    PR Newswire5 days ago

    Cronos Group Inc. Announces Mailing of Meeting Materials in Connection with Upcoming Special Meeting of Shareholders

    TORONTO, Jan. 18, 2019 /PRNewswire/ - Cronos Group Inc. (CRON) (CRON.TO) ("Cronos Group" or the "Company") is pleased to announce that the meeting materials for a special meeting of holders (the "Shareholders") of common shares of the Company (the "Common Shares") to be held on February 21, 2019 (the "Meeting"), including the management proxy circular dated December 31, 2018 (the "Circular"), prepared in connection with the proposed C$2.4 billion equity investment by Altria Group, Inc. (MO) ("Altria") in Cronos Group (the "Investment") previously announced on December 7, 2018, have been mailed to Shareholders and filed with the relevant Canadian securities regulators.

  • Cronos Group Inc. Announces Mailing of Meeting Materials in Connection with Upcoming Special Meeting of Shareholders
    CNW Group5 days ago

    Cronos Group Inc. Announces Mailing of Meeting Materials in Connection with Upcoming Special Meeting of Shareholders

    TORONTO , Jan. 18, 2019 /CNW/ - Cronos Group Inc. (CRON) (CRON.TO) ("Cronos Group" or the "Company") is pleased to announce that the meeting materials for a special meeting of holders (the "Shareholders") of common shares of the Company (the "Common Shares") to be held on February 21, 2019 (the "Meeting"), including the management proxy circular dated December 31, 2018 (the "Circular"), prepared in connection with the proposed C$2.4 billion equity investment by Altria Group, Inc. (MO) ("Altria") in Cronos Group (the "Investment") previously announced on December 7, 2018 , have been mailed to Shareholders and filed with the relevant Canadian securities regulators.

  • ACCESSWIRE5 days ago

    4 Marijuana Stocks Looking To Close Out A Strong Week

    Premier Health Group (OTC:PHGRF) (CSE:PHGI), HEXO Corp (OTC PINK: HYYDF), Canopy Growth Corp (CGC) (WEED.TO), and Cronos Group Inc (CRON) are for pot stocks worth keeping tabs on as we close out this week. Premier Health Group (OTC:PHGRF) (CSE:PHGI) has seen impressive gains during the month of January, as the cannabis sector has garnered significant notoriety, as well as a major increase in public support. Earlier this week, Premier Health Group (OTC:PHGRF) (CSE:PHGI) announced that as part of its international expansion strategy, it has entered into a strategic partnership with China'a 360 Health, a healthcare subsidiary of 360 Security Technology.

  • Benzinga5 days ago

    High Times: The Marijuana ETF Soars To Start 2019

    After slumping in the fourth quarter, the ETFMG Alternative Harvest ETF (NYSE: MJ ), the only dedicated cannabis exchange traded fund listed in the United States, is off to a scintillating start in 2019. ...

  • Cronos Group (CRON) Outpaces Stock Market Gains: What You Should Know
    Zacks6 days ago

    Cronos Group (CRON) Outpaces Stock Market Gains: What You Should Know

    Cronos Group (CRON) closed the most recent trading day at $13.66, moving +1.79% from the previous trading session.

  • ACCESSWIRE6 days ago

    4 Marijuana Stocks Looking To Have A Banner Month

    CORAL GABLES, FL / ACCESSWIRE / January 17,2019 / Marijuana stocks have become one of the hottest topics in the news over the course of the past few years. With the new year in full swing, Leafbuyer Technologies Inc (LBUY), Cronos Group Inc (CRON) (CRON), GW Pharmaceuticals plc (GWPH), and Charlotte's Web Holdings Inc (CWBHF) re 4 pot stocks that could make moves on Thursday. Leafbuyer Technologies Inc (LBUY) is a company worth looking into given that the Company's online platform is the most comprehensive source for cannabis deals and specials, commonly referred to as the "Priceline of Pot," by several sources well-versed in the industry.

  • InvestorPlace6 days ago

    You Can Trust Aurora Cannabis Stock Despite the Dilution

    At a time when rivals Tilray (NASDAQ:TLRY) and Aphria (NYSE:APHA) have captured headlines, Aurora Cannabis (NYSE:ACB) finally got a piece of the action again. Earlier this week, management announced its acquisition of premium-cannabis producer Whistler Medical Marijuana. As expected, ACB stock jumped on the news. More importantly for speculators, the enthusiasm hasn't faded yet, despite that we're now near the end of the week. A significant reason why Wall Street remains bullish is the acquisition's fundamental impact. For the most part, Aurora Cannabis stock is a direct play in medical marijuana. With Whistler, ACB has a broader portfolio. In addition, management must keep pace with key competitors. One of the biggest announcements in the sector was the partnership between Cronos Group (NASDAQ:CRON) and Altria Group (NYSE:MO). We all know about beverage-maker Constellation Brands' (NYSE:STZ) investment in Canopy Growth (NYSE:CGC). If you're not cutting deals in this sector, you're going nowhere. InvestorPlace - Stock Market News, Stock Advice & Trading Tips That's all fine and well. The most worrying factor here, however, is dilution in ACB stock. Including Whistler, Aurora has bought out nine companies. Ordinarily, such actions represent a strain on resources. The leadership team sidesteps the issue with all-stock purchases. * Top 10 Global Stock Ideas for 2019 From RBC Capital Last year, ACB acquired MedReleaf, Anandia Labs and ICC Labs. In total, the medical-cannabis firm spent $3.6 billion, all in equity. Because management refuses to tap into their cash reserves, Aurora Cannabis stock must take the hit, no pun intended. Currently, we have 994 million shares of ACB stock outstanding. Just two years ago, we had 313 million shares outstanding. By the time the Whistler deal and possible others are completed, we're looking at well over one billion shares. For those long Aurora, this dilutive strategy warrants concern. Still, it's too early to get pessimistic. ### With ACB Stock, Focus on the 'Why,' Not the 'How' Again, under ordinary circumstances, I'd sound the alarm on Aurora Cannabis stock. Diluting shares is a relatively easy way to expand your footprint. But get it wrong, and you could be courting disaster. Even without considering a worst-case scenario, dilutive strategies invite profitability and sustainability pressures. So what makes ACB stock different? It's all about the inherent nature of the legal-marijuana industry. Unlike almost every other market, cannabis has practically appeared out of nowhere. To deliver long-term success, companies must do everything they can to establish their brand. Therefore, traditional concerns like profitability take a backseat to growth and expansion. Logically, this strategy negatively impacts investments like ACB stock in the nearer-term. However, I'm afraid no other practical alternatives exist. Like crystal meth or hallucinogenic mushrooms, making weed is relatively easy. Thanks to platforms like YouTube, you can practice "pharmacy." But due to legalization, the black-market effect no longer bolsters marijuana prices. Therefore, cannabis firms must consolidate to survive as an industry. That's one reason why I'm not panicking over dilution in Aurora Cannabis stock. The other reason is differentiation. As I just mentioned, weed is easy to grow. What will separate the contenders from the pretenders is product quality. If you look at Whistler's product portfolio, you can see why management pulled the trigger. Contrary to prior eras, cannabis has dramatically evolved from just a means to get high. Today, medical-marijuana firms have "scienced" the snot out of the underlying commodity. In the foreseeable future, we'll enjoy a standardized industry where patients can match their symptoms with an ameliorating cannabis strain. To get there, ACB must lay down the foundations. That's why investors should focus on the "why" (in this case, future profitability), not the "how" (dilution). ### Be Carefully Optimistic Toward Aurora Cannabis Stock While I agree with management's overall direction, that doesn't guarantee a smooth ride. Analysts who raise the dilution concern aren't wrong. Every action has a reaction. At the very least, each share of ACB stock will be increasingly worth less. But I highly doubt that shares will become worthless. The deal-making and dilution represent the marijuana industry's harsh realities. Due to low barriers of entry on the production side, current cannabis firms must expand, partially to discourage competitors. And because traditional financiers are iffy about marijuana's Schedule I classification, for sector players, cash is king. Otherwise, going all-equity on every acquisition is unnecessarily risky. But again, that's just the reality. This investment category isn't for everyone because we know ahead of time that it's insanely and inevitably volatile. But a careful, longer-term approach to Aurora Cannabis stock should pay off quite nicely. As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Growth Stocks With the Future Written All Over Them * 7 Reasons Why Buffett's Bet on Apple Stock Is a Good One * 10 Companies That Could Post Decelerating Profits Compare Brokers The post You Can Trust Aurora Cannabis Stock Despite the Dilution appeared first on InvestorPlace.

  • Zacks Investment Ideas feature highlights: Tilray, Canopy and Cronos
    Zacks6 days ago

    Zacks Investment Ideas feature highlights: Tilray, Canopy and Cronos

    Zacks Investment Ideas feature highlights: Tilray, Canopy and Cronos

  • Why Marijuana ETF is on a High in 2019
    Zacks7 days ago

    Why Marijuana ETF is on a High in 2019

    After being beaten down in the final quarter of 2018, pot stocks staged a nice comeback this year on the renewed appeal for riskier assets.

  • ACCESSWIRE7 days ago

    Investors are Cashing in on These Bargains

    HENDERSON, NV / ACCESSWIRE / January 16, 2019 / There are several companies we've found starting 2019 off on a good foot. The market rally has helped investor confidence, which has led to oversold companies ...

  • MarketWatch8 days ago

    Cannabis stocks fall after attorney general nominee's comments about marijuana

    At a confirmation hearing Tuesday, attorney general nominee William Barr said that the current system around marijuana laws is 'untenable' and he personally supports prohibiting marijuana across the U.S. But, Barr said that under the current set of laws he would not go after cannabis businesses that comply with state regulations and a rescinded Justice Department memo. After Barr's comments, the ETFMG Alternative Harvest ETF , which includes a basket of the largest pot stocks, fell roughly 3% in 15 minutes. Some of the biggest names in the cannabis sector got a late-session haircut too: Canopy Growth Corp. , closed down 2.8%, Aurora Cannabis Inc. touch a mid-session high of a roughly 11% gain but closed the day down 3.2%. Cronos Group Inc. also experienced a similar trading pattern and closed down 5.2%. The lock-up period for Tilray Inc. expired Tuesday and shares fell 17% in the regular session. The Alternative Harvest ETF closed down 3.2% Tuesday.

  • TheStreet.com8 days ago

    Pot Stocks Are Mixed as Gov. Cuomo Readies Plan for Legalization in New York

    New York state's path to adult-use cannabis legalization will get clearer Tuesday when Gov. Andrew Cuomo lays out his plan to legalize the recreational use and sale of the drug at his State of the State address at 2 p.m. ET. Cuomo, who previously opposed legalization efforts, said in a radio interview that legalized marijuana could raise about $300 million in annual revenue for the state through taxes. Cuomo cited legalization in Massachusetts and pending legalization in New Jersey when questioned about whether the state should legalize.

  • ACCESSWIRE8 days ago

    4 Marijuana Stocks Leading Tuesday's Bull Charge

    CORAL GABLES, FL / ACCESSWIRE / January 15,2019 / Marijuana stocks have had quite a solid week during the beginning of January. American Premium Water Corporation (HIPH), GW Pharmaceuticals plc (GWPH), Cronos Group Inc (CRON) (CRON), and Charlotte's Web Holdings Inc (CWBHF) are 4 pot stocks that are bringing the heat. American Premium Water Corporation (HIPH) is a company you may not have heardof, but could benefit from taking a look at.

  • InvestorPlace8 days ago

    Why Canopy Growth’s Arrival in the U.S. Will Be Huge for CGC Stock

    After a late 2018 plunge, cannabis stocks have been on a tear to start 2019 due to a confluence of tailwinds, as I predicted in December. You've had analysts initiate coverage on the industry with a bullish skew. You've had early stage investors talk up the long-term potential of these companies. M&A chatter has picked up and legislation has moved in the right direction. All together, the big four pot stocks -- Canopy Growth (NYSE:CGC), Tilray (NASDAQ:TLRY), Cronos (NASDAQ:CRON) and Aurora (NYSE:ACB) -- are all up more than 30% in 2019 already, and it's not even halfway through January. This trend will persist because 2019 will mark the year that cannabis stocks enter into the U.S. market. The 2018 Farm Bill legalized hemp across America. But, Canadian cannabis companies have had a tough time entering the U.S. market due to cross-border restrictions. Canopy has worked around the restrictions, and was recently awarded a license to process and produce hemp in the state of New York. CGC stock rose 10% in response to the news. InvestorPlace - Stock Market News, Stock Advice & Trading Tips This is more than just a one-off catalyst. The New York State hemp license is the beginning a multi-quarter and multi-year excursion for Canopy into the multi-billion dollar U.S. CBD market. As the company embarks on this excursion, its leadership position will grow, its moat will grow, revenues will grow, profits will grow, visibility will grow and CGC stock will rise. As such, now isn't the time to sell CGC stock. Instead, it's the time to double-down on the long-term bull thesis of Canopy turning into a $100 billion company one day thanks to the global proliferation of legal CBD products, and Canopy's ability to stay at the top of this burgeoning market. ### CGC: Buy the Rumor & Buy the News For contextual purposes, let's provide a timeline of what has transpired over the past few weeks and why CGC stock is up 60% since Dec. 20. First, on Dec. 20, U.S. President Donald Trump signed into law the 2018 Farm Bill, which nationally legalized hemp. In response, Canopy Growth issued a press release commending the U.S. on passing this bill, and saying that Canopy is ready for a U.S. market launch. Roughly two weeks later, Canopy talked about its hemp production potential in Canada, and its desire and capacity to replicate that production in the now legal U.S. market. A few days after that press release, Canopy announced it had received a groundbreaking New York State license to do just that. In other words, the writing has been on the wall since the Farm Bill passed that Canopy was going to enter the U.S. market. Investors sniffed out that a potential licensing deal was in the works, and bid up CGC stock 60% in anticipation of that deal. Yet, even though this was a massive "buy the rumor" rally, you didn't get a typical "sell the news" response. Instead, you got "buy the rumor, buy the news", as CGC stock rose 10% in response to the New York State license news. * 10 Companies That Could Post Decelerating Profits Why? Because the implications of this license are huge, and indeed big enough to keep bulls in control and bears on their heels. ### The U.S. CBD Push Has Begun Canopy isn't just going to produce industrial hemp in New York, and stop there. Instead, this is just the first step of what will turn a multi-year expansion into the multi-billion dollar U.S. hemp market. Thanks to the passing of the Farm Bill, some industry insiders peg this market as measuring in at $22 billion in revenues within the next several years. Canopy's market cap is just $13 billion. Thus, this company is in the very early stages of entering a market that is twice the size of the company. This opportunity comes on top of early stage growth in a Canadian cannabis market that projects to also be a $10 billion market one day. All together, the U.S CBD push from Canopy has begun. It won't stop anytime soon. That means big growth is in store for the company over the next several quarters. Such big growth will keep bulls in control, bears on their heels and the stock on a winning trajectory. As such, the outlook for CGC stock to keep rallying in the near to medium term is quite favorable. ### Canopy Growth Is a $100 Billion Company In The Making The big picture behind CGC stock is that this is a company that is second-to-none in terms of size, innovation, leadership, resources, production capacity and expansion in a rapidly growing global CBD market that projects to be huge one day. There's plenty of reason to believe, given CBD's medicinal and recreational applications and widespread use among younger demographics, that the global CBD market will be as big as the global alcohol and tobacco markets one day. Both of those markets are in the $700 billion to $1 trillion-plus range. Conservatively, let's say the cannabis market maxes out around $500 billion in a decade. Let's also say that Canopy only controls about 5% of the global market, and runs at an alcoholic beverage market average of 30% operating margins. * 7 Video Game Stocks on Steep Discount Back of the envelope calculations produce $25 billion revenue potential and $7.5 billion operating profit potential for CGC within a decade. Taking out 20% for taxes and throwing a market-average 16x multiple on the net profits, one can easily see how CGC stock could be worth nearly $100 billion in a decade. That potential valuation is 10 years away. CGC stock has a market cap of just over $10 billion today. Thus, this is a potential ten-bagger over the next decade. Granted, ten years is a long time, and a lot could happen between now and then. But, a New York State hemp license is a big step in the right direction toward CGC stock realizing its $100 billion potential. ### Bottom Line on CGC Stock A New York State hemp license is big news, and a huge step toward this company maintaining its leadership position in the rapidly growing global CBD market. So long as this company keeps taking steps to defend market share, CGC stock has the potential to turn into a $100 billion company one day. As of this writing, Luke Lango was long CGC and CRON. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Key Emerging-Market Stocks to Buy for Contrarian Investors * 7 Stocks at Risk of the Global Smartphone Slowdown * 7 Pharmaceutical Stocks That Just Raised Prices This Year Compare Brokers The post Why Canopy Growth's Arrival in the U.S. Will Be Huge for CGC Stock appeared first on InvestorPlace.

  • ACCESSWIRE8 days ago

    With Gold Poised for a Once-in-a-Decade Move, Lucky Minerals Could be a Once-in-a-Lifetime Trade for Investors

    Gold and mining stocks have been left for dead as investors left mineral resources in favor of the returns seen in traditional equities. Ecuador has been a top destination for deals, and the emerging Lucky Minerals (LKMNF)(LKY) could be on the verge of a big 12-24 months as they report findings from the promising Fortuna Project. Should this happen, investors long Lucky Minerals could see unheard of returns.

  • Tilray Shares Rally as Investor Plans Not to Sell Shares
    Zacks9 days ago

    Tilray Shares Rally as Investor Plans Not to Sell Shares

    Tilray (TLRY) gains after Privateer Holdings decides not to sell shares in the first half of 2019.

  • ACCESSWIRE9 days ago

    These 4 Marijuana Stocks Could Be Positioned For A Big Year

    CORAL GABLES, FL / ACCESSWIRE / January 14, 2019 / Marijuana stocks have had quite a solid week during the beginning of January. American Premium Water Corporation (HIPH), Isodiol International Inc (ISOLF), Cronos Group Inc (CRON) (CRON), and KushCo Holdings Inc (KSHB) are 4 pot stocks that are bringing the heat. American Premium Water Corporation (HIPH) is a company you may not have heard of, but could benefit from taking a look at.

  • InvestorPlace9 days ago

    3 Reasons People Are Getting Excited About Buying CGC Stock

    [Editor's note: This story has been updated to reflect a recent development.] For the new year, the shares of cannabis producer Canopy Growth (NYSE:CGC) have made up some ground, going from $29 to $39. Yet they are still well off their recent highs. Consider that Canopy Growth stock is down about 32% since mid-October. Yes, it's been a wild trip, so to speak, and the fall off has also been more than just about the market correction. After all, there was some excess in the cannabis stocks, as valuations got to stratospheric levels. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Besides, the market has been getting more crowded, which could weigh on the pricing of cannabis. What's more, investors have more publicly traded stocks to choose from nowadays, such as Cronos (NASDAQ:CRON) and Tilray (NASDAQ:TLRY). * 10 A-Rated Stocks the Smart Money Is Piling Into So it's reasonable that CGC stock has been quite volatile. But despite this, I think it still represents a pretty solid way to play the cannabis market - especially for those with a long-term perspective. Here's a look at three factors to consider for the bull case: ### CGC Stock: Strong Platform Canopy Growth is one of the best positioned companies to benefit from the cannabis market. First of all, the company has a global footprint, with operations across 12 countries. Consider there are 4.3 million square feet of licensed locations and 1.3 million that are being built. Next, CGC is assembling an impressive line of brands that span areas like retail, medical and adult-use offerings. They include names like Tweed, Vert, Doja, Spectrum Cannabis and Main Street Shop. CGC has also been building up its IP portfolio, which will be crucial for differentiating itself from the competition. There are currently over 120 patent applications. And finally, CGC has been making progress with its healthcare investments. To this end, the company has 15 human clinical trials and four for animals. CGC has also developed a certification program and learning system for pharmacies. ### CGC Stock and Constellation Brands Constellation Brands's (NYSE:STZ) $4 billion investment in CGC has been a game-changer. Let's face it, when it comes to early-stage markets, there needs to be substantial resources. In the case of CGC, it will need to ramp up its infrastructure, boost marketing and pour money into R&D. But money is just one of the benefits. STZ should be a critical strategic partner that will help propel the growth of CGC. The company will provide a tremendous distribution footprint in the U.S., Mexico, New Zealand, Italy and Canada. Keep in mind that STZ owns brands like Corona Extra, Corona Light, Modelo Especial, Modelo Negra and Pacifico. What's more, the company has a proven team that understands M&A, brand building, marketing and production. ### CGC Stock: Secular Growth Opportunity The latest earnings report for CGC was a bit of a letdown, as there was actually a sequential decline on the top line. Note that the company was expected to see a lift from the legalization of recreational cannabis in Canada. But unfortunately, there were shortages and logistical issues with the launch. But such things should be temporary. For the most part, cannabis is likely to be a massive growth opportunity. Canada will certainly be a factor but the U.S. is also rapidly moving toward legalization (a recent positive was the passage of the farm bill, which took industrial hemp off the controlled substance list). Indeed, Canopy Growth stock is surging Monday as news is breaking that CGC has been granted a license to produce hemp in New York state. Specifically, CGC will establish a "Hemp Industrial Park" for the extraction and production of the now-legal substance. Here's what Chairman and Co-CEO of Canopy Growth, Bruce Linton, had to say: "Canopy Growth was founded to drive innovation within the cannabis and hemp industries. In New York we see an opportunity to create products that improve people's lives. In the process, we will create jobs in an exciting, highly profitable new industry. I applaud the political leadership at the federal and state level that has allowed today's announcement to become reality." As of this writing, CGC stock is up 9% on the news. So how big will the market get? Well, according to Cowen analyst Vivien Azer, it will reach a whopping $80 billion in the U.S. by 2030. Oh, and she also believes that CGC will see acceleration on the top line. Her forecast for fiscal 2019 is that revenues will soar by over 200% to $778 million. Tom Taulli is the author of High-Profit IPO Strategies, All About Commodities and All About Short Selling. Follow him on Twitter at @ttaulli. As of this writing, he did not hold a position in any of the aforementioned securities. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Key Emerging-Market Stocks to Buy for Contrarian Investors * 7 Stocks at Risk of the Global Smartphone Slowdown * 7 Pharmaceutical Stocks That Just Raised Prices This Year Compare Brokers The post 3 Reasons People Are Getting Excited About Buying CGC Stock appeared first on InvestorPlace.